Skip to Main Content

Author Details

Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
2009
21
8
Prashant Mali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
38048593Transcriptional control of leukemogenesis by the chromatin reader SGF29.Blood2024
36264490Detection of TP53 Mutation in Acute Myeloid Leukemia by RT-PCR-Based Sanger Sequencing.Methods Mol Biol2023
36588017Examining the relationship between severe persistent mental illness and surgical outcomes in women undergoing mastectomy for breast cancer.Am J Surg2023
35167008Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas.Curr Treat Options Oncol2022
35770040Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.Ther Clin Risk Manag2022
35670706Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.Drugs Today (Barc)2022
35577818Author Correction: A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing.Nat Commun2022
36751660Images in Immunotherapy and Precision Oncology: Angiosarcoma of the Spleen and Liver.J Immunother Precis Oncol2022
36425227Analysis of Gender-Based Authorship Trends in Leading Pain-Medicine Journals Over 10 Years.Health Psychol Res2022
36172151Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies.Front Oncol2022
33074720PopInf: An Approach for Reproducibly Visualizing and Assigning Population Affiliation in Genomic Samples of Uncertain Origin.J Comput Biol2021
34764240A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing.Nat Commun2021
34518534The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.Nat Commun2021
34226546The role of the PZP domain of AF10 in acute leukemia driven by AF10 translocations.Nat Commun2021
30663717Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays.J Vis Exp2019
25464900AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes.Cancer Cell2014
24013208Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases.Nat Struct Mol Biol2013
21926964Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.Leukemia2012
22339244Targeting JAK2 in the therapy of myeloproliferative neoplasms.Expert Opin Ther Targets2012
21860432The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity.Leukemia2012
198230253'UTR mediated regulation of the cyclin D1 proto-oncogene.Cell Cycle2009
  • 1 - 21 of 21

Recommended Authors

Haijiao Zhang
Oregon Health & Science University, Knight Cancer Institute
Career Start Year 2017
Number of shared co-authors 0
Zhengming Chen
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 2013
Number of shared co-authors 0
Srinivas K Tantravahi
Huntsman Cancer Institute at the University of Utah.
Career Start Year 2012
Number of shared co-authors 0
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2011
Number of shared co-authors 0
Stuart J Blakemore
Center for Molecular Medicine Cologne (CMMC), University of Cologne
Career Start Year 2010
Number of shared co-authors 1
Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 1
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Career Start Year 2009
Number of shared co-authors 0
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Yang Chen
The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 0
Geoffrey Shouse
City of Hope National Medical Center
Career Start Year 2007
Number of shared co-authors 0
Rashmi Kanagal-Shamanna
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 0
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 0
Linghua Wang
The University of Texas M. D. Anderson
Career Start Year 2006
Number of shared co-authors 0
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 0
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 0
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 0
Giovanni Roti
University of Parma
Career Start Year 2003
Number of shared co-authors 0
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 1
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Career Start Year 2002
Number of shared co-authors 1
Fei Yang
Oregon Health & Science University
Career Start Year 2002
Number of shared co-authors 0
Elie Traer
Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 0
David M Weinstock
Merck & Co.
Career Start Year 1998
Number of shared co-authors 1
Changchun Deng
Center for Lymphoid Malignancies, Columbia University Medical Center
Career Start Year 1997
Number of shared co-authors 0
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 0
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 1
Yongjin Li
Mayo Clinic
Career Start Year 1995
Number of shared co-authors 0
Kimberly Stegmaier
Dana-Farber Cancer Institute
Career Start Year 1995
Number of shared co-authors 1
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 2
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1991
Number of shared co-authors 1
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 0

Collaborators

Aniruddha J Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 9
Eytan Ruppin
National Cancer Institute
Co-authored papers 4
Ze'ev Ronai
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 3
Amit U Sinha
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Nan Zhu
Shanghai General Hospital, Shanghai Jiaotong University
Co-authored papers 2
Neil A Robertson
Beatson Institute for Cancer Research and the University of Glasgow
Co-authored papers 1
Rabi Murad
Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 1
Kelsey Saddoris
Sanford Burnham Prebys Medical Discovery Institute.
Co-authored papers 1
Prashant Mali (CM4AI)
University of California San Diego
Co-authored papers 1
Luyi Zhao
Kunming Medical University
Co-authored papers 1
Bo-Rui Chen
National Taiwan Ocean University
Co-authored papers 1
Yongmei Feng
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 1
Ian Pass
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 1
Richard Koche
Memorial Sloan Kettering Cancer Center
Co-authored papers 1
John G Doench
Co-authored papers 1
Fiorella Schischlik
National Cancer Institute, National Institutes of Health
Co-authored papers 1
James E Bradner
Co-authored papers 1
Peter D Adams
Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 1
Robert G Roeder
the Rockefeller University
Co-authored papers 1
Scott A Armstrong
Boston Children's Hospital
Co-authored papers 1
Mayuri Kerr
Sanford Burnham Prebys Medical Discovery Institute.
Co-authored papers 1
Release 1.2